AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real-life Treatment Outcomes of Ravulizumab in PNH
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06633536
- Locations
- 🇵🇱
Research Site, Wroclaw, Poland
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Phase 3
Recruiting
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 878
- Registration Number
- NCT06627647
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
AZAHAR Study To Describe Anifrolumab in a Real-World Setting
Recruiting
- Conditions
- Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06626945
- Locations
- 🇪🇸
Research Site, Valladolid, Spain
OPTIMISE-CKD Study_current Clinical Landscape in Spain
Recruiting
- Conditions
- Renal Disease
- Interventions
- Other: Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024)Other: Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 86516
- Registration Number
- NCT06614712
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
Phase 1
Recruiting
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)Renal Impairment
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06611423
- Locations
- 🇸🇪
Research Site, Solna, Sweden
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT06610526
- Locations
- 🇨🇳
Research Site, Xian, China
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06606847
- Locations
- 🇷🇺
Research Site, Ufa, Russian Federation
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
Recruiting
- Conditions
- Asthma
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06605885
- Locations
- 🇨🇳
Research Site, Zhuhai, China
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06594068
- Locations
- 🇺🇸
Research Site, Las Vegas, Nevada, United States
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06602479
- Locations
- 🇪🇸
Research Site, Valencia, Spain
© Copyright 2025. All Rights Reserved by MedPath